CD47 and neoplasm: While tumor immunotherapy has been highly anticipated by researchers worldwide in recent decades, the discovery of tumor checkpoints in particular, including PD-L1, CTLA-4, CD47, and the Siglec family, is a landmark advance in tumor immunotherapy.